What is Integra LifeSciences Holdings Corporation's (IART) StockRank?

MoatMap's StockRank for Integra LifeSciences Holdings Corporation (IART) is 80/100, with a Buy signal. This is a composite score combining Quality (41), Value (55), and Momentum (78) factor ranks across MoatMap's 20,000+ stock universe.

Does Integra LifeSciences Holdings Corporation have an economic moat?

Integra LifeSciences Holdings Corporation (IART) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Integra LifeSciences Holdings Corporation a buy, hold, or sell?

MoatMap's current signal for Integra LifeSciences Holdings Corporation (IART) is Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Integra LifeSciences Holdings Corporation in?

Integra LifeSciences Holdings Corporation (IART) operates in the Healthcare sector, specifically the Medical Devices industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IART

BUYFLAG

Integra LifeSciences Holdings Corporation · Healthcare · United States · $1.5B · Avg Vol: $19M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-38.6%

D/E

2.0x

Dividend %

—

AI CONVICTION THESIS

Integra LifeSciences has very strong momentum M79 and value V55, but quality at Q40 is below the calibrated floor, so stage one fails.

COMPANY DESCRIPTION

Integra LifeSciences Holdings Corporation is a global medical technology company delivering innovative solutions in surgical instruments, regenerative tissue technologies, and neurosurgical products. Its competitive strength stems from a specialized and diversified product portfolio addressing critical clinical needs, supported by robust R&D and strong relationships within the surgical community. This focus allows Integra to maintain a strong market presence in niche, high-value medical procedures.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	1.6B	1.5B	1.6B	1.6B	1.6%	1.6B	1.7B	1.7B	2.9%
EPS	2.16	0.87	-0.09	-6.63	-59.9%	-6.47	—	—	—
Shares	83.7M	78.2M	77.2M	77.9M	-6.9%	77.8M	—	—	—
Debt	1.6B	1.7B	2.0B	2.0B	8.0%	2.0B	—	—	—
Equity	1.8B	1.6B	1.5B	1.0B	-16.7%	—	—	—	—
Op CF	264.5M	140.0M	129.4M	50.4M	-42.5%	71.4M	—	—	—
Inv CF	-58.6M	-94.2M	-390.8M	-108.1M	—	—	—	—	—
Fin CF	-252.0M	-229.9M	237.9M	28.3M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+13.0%

SMA 50SMA 200

$19.79

RSI (14)

61.5

52W High

$20.26

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

-15.2%32.5

ROE

-38.6%22.4

GP/Assets

25.9%59.5

Op. Margin

10.4%67.8

FCF/Assets

1.9%55.0

Piotroski

430.1

Int. Cover

-5.5x28.1

D/E Ratio

1.96x5.9

Current Ratio

3.38x58.5

Value

P/E (TTM)

—N/A

EV/EBITDA

10.5x65.8

P/FCF

22.2x57.0

P/B

1.4x73.8

P/S

0.9x85.5

Div Yield

—N/A

Momentum

52W High %

98%97.3

RS 6M

55%94.9

SMA 50/200

1.30x94.1

EPS Rev 4W

-0.0%50.9

EPS Rev 12W

+2.2%71.7

EPS Improve

+140%82.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.5B

P/E (Forward)

7.2x

Gross Margin

56.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IART are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
IART	Integra LifeSciences Holdings Corporation(you)	$1.5B	80	BUY
ENOV	Enovis Corporation	$1.6B	80	BUY
AHCO	AdaptHealth Corp.	$1.5B	79	BUY
IRMD	IRADIMED CORPORATION	$1.2B	78	BUY
UFPT	UFP Technologies, Inc.	$1.8B	75	BUY
CNMD	CONMED Corporation	$1.3B	86	STRONG BUY
AVNS	Avanos Medical, Inc.	$1.2B	72	BUY
ITGR	Integer Holdings Corporation	$3.3B	72	BUY
AXGN	Axogen, Inc.	$2.1B	62	HOLD
TCMD	Tactile Systems Technology, Inc.	$620M	87	STRONG BUY

Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%

Integra LifeSciences Holdings Corporation (IART) — Stock Score Summary

Integra LifeSciences Holdings Corporation (IART) has a MoatMap StockRank of 80/100 based on Quality (41/100), Value (55/100), and Momentum (78/100) factor scores. The current signal is BUY. Integra LifeSciences has very strong momentum M79 and value V55, but quality at Q40 is below the calibrated floor, so stage one fails.

Key Financial Metrics

Price	$19.79
Market Cap	$1.5B
P/E (Forward)	7.22
Price/Book	1.41
Return on Equity	-38.6%
Return on Invested Capital	-15.2%
Debt/Equity	1.96x
Gross Margin	56.7%
Operating Margin	10.4%
Revenue Growth	2.4%
Free Cash Flow	$69M

Integra LifeSciences Holdings Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Integra LifeSciences Holdings Corporation’s (IART) StockRank?: MoatMap’s StockRank for Integra LifeSciences Holdings Corporation (IART) is 80/100, with a Buy signal. It is a composite of Quality (41), Value (55), and Momentum (78) factor ranks across MoatMap’s 20,000+ stock universe.
Does Integra LifeSciences Holdings Corporation have an economic moat?: Integra LifeSciences Holdings Corporation (IART) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Integra LifeSciences Holdings Corporation a buy, hold, or sell?: MoatMap’s current signal for Integra LifeSciences Holdings Corporation (IART) is Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Integra LifeSciences Holdings Corporation in?: Integra LifeSciences Holdings Corporation (IART) operates in the Healthcare sector, specifically the Medical Devices industry (United States).